University of Windsor

Scholarship at UWindsor
Biological Sciences Publications

Department of Biological Sciences

3-2016

Pathomimetic cancer avatars for live-cell imaging of protease
activity
Kyungmin Ji
Joshua Heyza
Dora Cavallo-Medved
University of Windsor

Bonnie F. Sloane

Follow this and additional works at: https://scholar.uwindsor.ca/biologypub
Part of the Biology Commons

Recommended Citation
Ji, Kyungmin; Heyza, Joshua; Cavallo-Medved, Dora; and Sloane, Bonnie F., "Pathomimetic cancer avatars
for live-cell imaging of protease activity" (2016). Biochimie, 122, 68-76.
https://scholar.uwindsor.ca/biologypub/105

This Article is brought to you for free and open access by the Department of Biological Sciences at Scholarship at
UWindsor. It has been accepted for inclusion in Biological Sciences Publications by an authorized administrator of
Scholarship at UWindsor. For more information, please contact scholarship@uwindsor.ca.

HHS Public Access
Author manuscript
Author Manuscript

Biochimie. Author manuscript; available in PMC 2017 March 01.
Published in final edited form as:
Biochimie. 2016 March ; 122: 68–76. doi:10.1016/j.biochi.2015.09.015.

Pathomimetic cancer avatars for live-cell imaging of protease
activity
Kyungmin Jia,1, Joshua Heyzab,c,2, Dora Cavallo-Medveda,d,3, and Bonnie F. Sloanea,b,c,d,*
a

Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI 48201,
USA

Author Manuscript

b

Cancer Biology Graduate Program, Wayne State University School of Medicine, Detroit, MI
48201, USA
c

Department of Oncology, Wayne State University School of Medicine, Detroit, MI 48201, USA

d

Department of Biological Sciences, University of Windsor, Windsor, Canada

1

Department of Pharmacology, Wayne State University School of Medicine, 540 E. Canfield,
Detroit, MI 48201, USA

2

Cancer Biology Graduate Program, Department of Oncology, Wayne State University School of
Medicine, 540 E. Canfield, Detroit, MI 48201, USA

3

Department of Biological Sciences, University of Windsor, 401 Sunset Ave., Windsor, ON N9B
3P4, Canada

Author Manuscript

Abstract
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Proteases are essential for normal physiology as well as multiple diseases, e.g., playing a causative
role in cancer progression, including in tumor angiogenesis, invasion, and metastasis.
Identification of dynamic alterations in protease activity may allow us to detect early stage cancers
and to assess the efficacy of anti-cancer therapies. Despite the clinical importance of proteases in
cancer progression, their functional roles individually and within the context of complex protease
networks have not yet been well defined. These gaps in our understanding might be addressed
with: 1) accurate and sensitive tools and methods to directly identify changes in protease activities
in live cells, and 2) pathomimetic avatars for cancer that recapitulate in vitro the tumor in the
context of its cellular and non-cellular microenvironment. Such avatars should be designed to
facilitate mechanistic studies that can be translated to animal models and ultimately the clinic.
Here, we will describe basic principles and recent applications of live-cell imaging for
identification of active proteases. The avatars optimized by our laboratory are three-dimensional
(3D) human breast cancer models in a matrix of reconstituted basement membrane (rBM). They
are designated mammary architecture and microenvironment engineering (MAME) models as they
have been designed to mimic the structural and functional interactions among cell types in the
normal and cancerous human breast. We have demonstrated the usefulness of these pathomimetic
avatars for following dynamic and temporal changes in cell:cell interactions and quantifying
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changes in protease activity associated with these interactions in real-time (4D). We also briefly
describe adaptation of the avatars to custom-designed and fabricated tissue architecture and
microenvironment engineering (TAME) chambers that enhance our ability to analyze concomitant
changes in the malignant phenotype and the associated tumor microenvironment.
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1. Proteases, cancer and the tumor microenvironment
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Protease (or proteolytic) activity mediates both physiological and pathological processes.
Alterations in protease activity, involving members of all five major classes of
endopeptidases [i.e., aspartic, cysteine, matrix metalloproteinases (MMPs), serine, and
threonine proteases], are associated with malignant progression including tumor
angiogenesis, invasion and metastasis [for review see Refs. [1,2]]. Proteases within the
tumor microenvironment originate from both tumor and associated stromal cells (e.g.,
fibroblasts, macrophages, and endothelial cells). Typically, dysregulation of proteolysis at
the tumor:stroma interface is not due to changes in any one particular protease; rather, it is
the result of changes in the collective activity of a variety of proteases from multiple classes.
Complex pathophysiological alterations within the local tumor microenvironment can lead
to increased basal levels of proteolysis thereby augmenting the invasive capacity of the
tumor. There are several different mechanisms by which proteolysis can be increased during
malignant progression including aberrant localization of proteases, gene amplification,
increased mRNA stability, altered expression or stability of endogenous inhibitors, and
increased acidity at tumor margins leading to pH dependent protease activation.

Author Manuscript

Changes within the non-cellular tumor microenvironment, such as a decrease in extracellular
pH or oxygen, can also promote the proteolytic breakdown of stromal tissues surrounding
tumors. The tumor microenvironment is often acidic due to shifts in tumor metabolism (i.e.,
the Warburg Effect) [3,4]. Moreover, alterations in ion pumps/exchangers such as the VATPase proton pumps, which can be found in the plasma membrane, and NHE-1, the
sodium-hydrogen ion exchanger, can contribute to the acidification of the tumor
microenvironment [5,6]. Another contributing factor is poor tumor perfusion that generates a
hypoxic tumor microenvironment. Oxidative stress within this hypoxic environment shifts
the metabolic state of tumor cells from normal oxidative phosphorylation to glycolytic
metabolism, resulting in the secretion of acidifying byproducts, activation of hypoxiainducible factor (HIF)-1α, and transcription of target genes involved in angiogenesis and
metastasis [7]. Acidification has been linked to an aggressive tumor phenotype and drug
resistance [8–11]. Gillies and colleagues [5] have hypothesized that acidification of the
tumor microenvironment promotes tumor invasion and metastasis by stimulating stromal
remodeling. The general understanding is that localized tumor acidity creates an
environment in which acid-resistant cells have a selective advantage. Tumor acidification has
been shown to increase peritumoral protease activity [12] as illustrated in Fig. 1. For
example, under normal conditions, procathepsin B (immature zymogen) is localized
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primarily to late endosomes/lysosomes, in which the acidic environment favors
autoactivation or enzymatic activation by the aspartic protease cathepsin D of the zymogen
into mature, active cathepsin B. Asparaginyl endopeptidase (AEP)/legumain, an
endolysosomal cysteine protease, further processes cathepsin B from its active single chain
form to its active double chain form [13]. During tumor progression, however, both
procathepsin B and cathepsin B can be secreted or redirected to the plasma membrane. In
conjunction with the Gillies laboratory [5], we have shown that an acidified tumor
microenvironment also allows for extracellular activation of procathepsin B, and subsequent
proteolysis of its substrates (e.g., collagen IV), which may provide space for tumor cell
proliferation and invasion [12]. Using a murine window chamber model, we have shown that
neutralizing the acidic pH of the tumor microenvironment with sodium bicarbonate can
reduce the invasive potential of tumors [5]. Elucidating the dynamic nature of proteolysis
within the tumor microenvironment will be key to understanding stromal remodeling, local
invasion, and potential drug response.

Author Manuscript

Some roles of individual or classes of proteases in malignant progression are clear; however,
the complexity of proteolytic networks in cancer is overwhelming, calling into question
whether targeting proteases will be efficacious. The lackluster results of clinical trials testing
MMP inhibitors, nearly fifteen years ago, underscore this point. Although many MMPs have
been implicated in malignant progression (e.g., MMP-1, 2, 3, 7, 9, 10, 11, 13, 14, and 26)
[14], and thus considered potential therapeutic targets, their roles within the proteolytic
network of the tumor microenvironment are more complex than originally thought. For
example, during tumorigenesis some MMPs promote tumor progression while others are
tumor suppressing [2,15,16]. In addition, tumor cells are capable of circumventing the
effects of MMP inhibitors by activating alternative proteolytic pathways [17–19]. Thus,
targeting only one class of proteases involved in proteolysis at the tumor:- stroma interface,
may have only limited effects. Compensatory mechanisms further contribute to the
complexity of proteolytic networks in cancer. Moreover, these networks are dynamic in
regard to changes in protease expression, localization and activity depending on cancer type
and stage of disease. Finally, a variety of proteases are also secreted from a multitude of
tumor-associated cells, thereby contributing to the complex cancer degradome.

Author Manuscript

Over the past decade there has been an explosion in research to describe the dynamic and
complex nature of protease interactions, regulation, and signaling. Overall and colleagues
[20] have constructed a human protease web based upon computational analyses of data
available from 23 tissue types in which they identified 1230 human proteases, inhibitors, and
substrates as well as ~141,000 connections between them. They identify both interaction
pairs and general hierarchies/nodes that interconnect all classes of proteases. Their work has
important implications for the study of proteases in cancer since few current methods
analyze the complex and dynamic nature of tumor proteolysis. Indeed, the sheer number of
proteases and cell types involved in promoting malignant progression limits the scientific
value of using traditional 2D culture systems to study protease activity since gene and
protein expression profiles of cells under 2D culture conditions are greatly different from
ones under 3D culture conditions [21,22]. We argue that this is the case because proteases
from multiple cell types (e.g., tumor cells, fibroblasts, macrophages) all contribute to the
collective proteolytic network of tumors. Thus, using cancer models that do not recapitulate
Biochimie. Author manuscript; available in PMC 2017 March 01.
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the native tumor microenvironment may yield only a partial narrative. We propose that livecell imaging of protease activity in complex, 3D pathomimetic culture models that include
more than one cell type will provide a more complete understanding of: 1) the role(s) of
protease networks in malignant progression; 2) how protease interactions contribute to
stromal remodeling; and 3) how interactions between tumor and stromal cells within the
tumor microenvironment modulate proteolysis.

2. Protease-targeted probes for live-cell imaging

Author Manuscript

Conventional methods to measure total protease and/or proteolytic levels provide limited
information on dynamic changes in proteolytic activity that occur in live cells. To address
these limitations, fluorescently labeled substrates and probes have been developed to identify
and quantify active proteases in live cells as well as in whole animals. These imaging probes
are advantageous because they can detect both total levels and/or spatio-temporal changes in
active proteases. Moreover, these probes have been useful for biomarker discovery and the
detection of cancer progression [23]. There are a number of reviews on using imaging to
study proteases [24–26]. Here we review applications of substrate-based and activity-based
probes for the detection of active proteases associated with cancers.
2.1. Substrate-based probes

Author Manuscript

Substrate-based probes (SBPs), one of the most common tools to monitor protease activity,
contain peptide sequences that can be cleaved by the targeted proteases. SBPs generally
consist of two parts: peptides cleaved by the protease(s) of interest, and a fluorophore that
generates visible signals when the probe is cleaved by proteases. Various fluorescent dyes
such as aminomethylcoumarin (AMC), boron-dipyrromethene (BODIPY), rhodamine,
cyanine, dansyl, and nitrobenz-2-oxa-1,3-diazole (NBD) have been commonly used as
fluorophores [27]. Near-infrared fluorochromes are used preferably for in vivo imaging
applications because they exhibit greater depths of penetration into tissues and have a higher
signal to background ratio [28]. Synthetic substrates are often used for imaging as well as
other biochemical assays due to their enhanced selectivity for target proteases as compared
to natural substrates [29,30]. The protease recognition site within the probes is crucial for
conferring selectivity. For example, SBPs with high selectivity toward cathepsin B have been
used to detect cathepsin B activity in live cancer cells [31] and in dysplastic intestinal
adenomas in mice [32].

Author Manuscript

Recently, many SBPs have been constructed to contain a quencher along with the
fluorophore. The quencher and the fluorophore are positioned at opposite ends of a
recognition site to prevent high levels of background fluorescence. Upon cleavage of the
quenching functional group, the fluorescent signal is released, enabling their detection.
Some SBPs contain two or more fluorophores that are self-quenched when in close
proximity. These fluorophores are linked by peptides containing protease-selective
recognition sites. When the target protease cleaves the recognition site between
fluorophores, free monomers that are released emit fluorescent signals. This class of SBPs
has been widely used in animal models for the detection of cysteine cathepsins [32,33].
These probes function on the basis of fluorescence resonance energy transfer (FRET)
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technology. FRET monitors changes in proteineprotein interactions and protein
conformation in a distance-dependent manner by using two proximal fluorophores (a donor
and an acceptor). Typically, the emission wavelength of a donor is similar to the excitation
wavelength of an acceptor, so that in close proximity the acceptor quenches the fluorescence
emitted by the donor. Once a peptide sequence between these pairs is hydrolyzed and/or
conformationally changed by proteases, the distance between the donor and acceptor
fluorophores increases resulting in the emission of fluorescence. Changes in the
fluorescence intensity are correlated with proteolytic activity and can be detected and
quantified by live imaging or other biochemical assays of protease activity [34]. These
probes can also be used to determine the proximity of the donor and acceptor within a cell.
Using this method, many proteases including MMPs [35–39] and cathepsin B [38] have
been visualized in live cancer cells. For more detailed descriptions of FRET-based protease
probes including dye quenched protein substrates, please see Dive et al. [25] and Hu et al.
[40].

Author Manuscript

Dye quenched (DQ) protein substrates have been employed to detect and distinguish
pericellular proteolytic activity from intra-cellular proteolytic activity (Fig. 1A–C) [12,41].
These substrates are analogs of proteins commonly found in the extracellular matrix (ECM)
(e.g., collagens). Labeling of these substrates with excessive numbers of fluorescent dyes
quenches the signal, and allows them to remain undetected prior to proteolytic degradation.
Upon hydrolysis of the substrate, the dyes are separated from each other and detected as a
fluorescent signal. Our laboratory has established methods to quantify degradation of DQcollagens on a per cell basis, including quantification of total, pericellular and intracellular
degradation products [41]. Moreover, through the use of protease inhibitors we further
revealed that cysteine cathepsins, MMPs and serine proteases are involved in DQ-collagen
degradation by breast and colon cancer cells [42]. These probes have also been used to
monitor ECM degradation associated with cancer cell migration and invasion [12,42–45].
A major advantage of SBPs is the signal amplification and therefore their ability to detect
less abundant proteases. On the contrary, one major drawback of SBPs is that they do not
allow direct identification of the target proteases since they are selective rather than specific
for any single protease. Furthermore they do not remain bound to the target proteases after
proteolysis and thus fluorescent signals can diffuse away from the cleavage site, making
accurate localization of the target protease(s) difficult.
2.2. Activity-based probes

Author Manuscript

Activity-based probes (ABPs), unlike SBPs, directly label active proteases through activitydependent covalent modification. Typical ABPs are composed of three critical components:
1) a reactive functional group, referred to as a warhead, for binding at the active site of a
target enzyme, 2) a tag for visualization, and 3) a linker that separates the reactive functional
group from the tag, allowing for increased accessibility of probes to target proteases [46].
New generation ABPs contain a quencher in close proximity to the tag to reduce nonspecific, fluorescent signals from unbound probes. Once the quenched ABPs (qABPs)
covalently bind to the active site of the target enzyme, the quencher is released by the active
enzyme and a fluorescent signal is generated. Hence, qABPs have a higher signal to
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background ratio as compared to non-quenched ABPs, allowing for imaging of more defined
proteolytic activity in live cells [reviewed in Refs. [25,26]].

Author Manuscript

ABPs have been developed for the detection of cysteine, serine, threonine, and metalloproteases, both in live cells and animals [28,37,47–51]. Methods to monitor active caspases
[52] and cysteine cathepsins [12,28,51,53] in cancers and inflammation using ABPs are
well-developed. In Fig. 1D–F, we illustrate the use of an ABP for cysteine cathepsins to
image active forms of cathepsins B and L [12]. Blum et al. [28] generated and developed a
series of nonquenched (GB123) and quenched ABPs (GB137) that target active cysteine
cathepsins. In breast cancer animal models, GB123 tagged with Cy5 and GB137 with nearinfrared fluorescent tags reached a maximal signal to background ratio in 6 h and the signal
then lasted for an extended period. Edgington and coworkers [52] demonstrated optical
imaging of apoptosis by caspases-3 and -7 with ABPs, AB50-Cy5 and tAB50-Cy5, in mouse
xenograft models bearing human colorectal tumor cells. The caspase ABPs are stable in vivo
and show highly selective labeling of target enzymes. Such applications of ABPs show their
potential for the detection of protease as biomarkers and protease-targeted drugs in diseases
including cancers [54].

Author Manuscript

Compared to SBPs, a major advantage of ABPs is that they bind covalently to the active site
of a target protease. This facilitates evaluation of their spatial distribution. Since the target
proteases are covalently tagged with a fluorescent label, ABPs can also be used to identify
the labeled proteases by posthoc testing (e.g., by Western blotting and flow cytometry) and
thereby profiling of the biological activity of target proteases in live cells [55]. Since an ABP
will covalently bind to the active site of only one target protease, a potential disadvantage of
using ABPs is the low signal output. Furthermore, ABPs are based on inhibitors and thus
there may be possible structural and functional alterations in the target protease that have
unexpected biological consequences (e.g., pharmacological knock-down of the target
protease). Nonetheless, ABPs have been shown to have a minimal effect on cysteine
cathepsin activity in vivo, likely due to the low doses used for imaging [56]. To our
knowledge, this has not been verified for live-cell imaging of protease activity in vitro. This
needs to be considered if live-cell proteolysis assays are to be used in MAME cultures as a
surrogate readout for efficacy of drug treatments over extended periods of time (see below).
Over time such assays and other pathobiological endpoints may be affected even if an ABP
only minimally reduces protease activity.

Author Manuscript

Evaluation of collective protease activity using SBPs and of specific protease activity using
ABPs has provided valuable information on the role of proteases in cancer both in vitro and
in vivo [25,26,46]. Nonetheless, current imaging probes for the detection of proteolytic
activities still lack high spatial and temporal resolution, sensitivity and selectivity for target
proteases. Hence, next-generation probes should be developed with consideration for greater
selectivity, photo-stability, and increased signal to background ratios.

3. MAME cultures: avatars for live-cell imaging of protease activity
In vitro and in vivo studies using imaging probes to detect proteolytic activity have greatly
advanced the areas of cancer detection, patient prognosis, and prediction of responses to
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various therapies, but both have their limitations. It is difficult to obtain a comprehensive
understanding of the vast complexity of proteolysis solely by using animal models. The
myriad aspects of cross-talk between cancer cells and associated stromal cells cannot be
easily assessed in animal models, nor do animal models support tightly regulated and
reproducible parametric studies. Furthermore, the findings in animal models may not
translatable to human cancers.

Author Manuscript

On the other hand, in vitro two-dimensional (2D) cell cultures, although advantageous due
to their highly controllable culture environments, lack the 3D architectural context including
the cell microenvironment. Consequently, results from 2D culture experiments are often
untranslatable and irreproducible in vivo. The difficulty of studying tumor-associated
protease activity upon the backdrop of a 2D culture system underscores this point.
Moreover, it has been well established that the proteases contributing to collective tumor
proteolysis originate from a variety of cell types including tumor cells, fibroblasts,
macrophages, and endothelial cells. Thus, the use of models that do not mimic the native
tumor microenvironment may produce intrinsically limited insights in relation to the
identification of mechanisms and pathways involved in malignant progression.

Author Manuscript

The use of 2D cell cultures also restricts our understanding of the mechanisms regulating the
remodeling of the tumor micro-environment that accompanies local invasion. Conventional
in vitro 2D cultures cannot reproduce morphogenesis and cellecell interactions in
physiological conditions that occur by either physical contact or cytokine autocrine/
paracrine mechanisms in a complex tumor microenvironment comprised of multiple cell
types. The absence of the microenvironment in 2D cultures also has an effect on gene
expression, protein synthesis and trafficking/secretion of proteases. We have previously
shown an increase in secretion of procathepsin B through integrin signaling (α1, α2, and β1)
by human breast fibroblasts grown in 3D collagen I gels as compared to 2D cultures grown
on plastic or glass culture dishes [57]. Studies of pre-invasive breast carcinoma cells
(MCF10.DCIS) and fibroblasts revealed that fibroblasts grown in 3D cultures secreted more
MMP14, hepatocyte growth factor (HGF), cyclooxygenase (COX) 2, and CXCL12, as
compared to those grown in 2D. The secretions by fibroblasts increased the invasive
phenotype of co-cultured MCF10.DCIS cells [22].

Author Manuscript

Many proteases are redirected to the plasma membrane and/or secreted into the tumor
microenvironment of cancers, yet changes in trafficking of proteases may not necessarily
increase proteolytic activity unless other factors, including proper localization of protease
receptors and activators (such as uPAR and MMP14), the absence of endogenous protease
inhibitors [such as tissue inhibitor of metalloproteinases (TIMPs) and serpins], and
pericellular acidification also occur. These factors can be altered during tumor progression
by hypoxia and acidification of the tumor microenvironment, and cellular interactions with
various ECM components, such as laminin, collagens I and IV, and fibronectin. Thus, to
better understand the ways in which proteolysis contributes to stromal remodeling and local
invasion, models should be: 1) composed of ECM components that best mimic in vivo
conditions, 2) developed for co-culturing with tumor-associated cells, and 3) controlled to
allow monitoring of changes in the tumor microenvironment such as hypoxia and
acidification. Ideal models for the multistep process of tumor development would allow for
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phenotypic heterogeneity of and genetic changes in tumor cells, biological contexts,
heterotypic cell crosstalk and non-cellular factors (e.g., hypoxia and acidosis) of the
microenvironment.

Author Manuscript

Three-dimensional in vitro models have been developed as an important alternative that
takes advantage of both the in vivo tumor microenvironment, by the use of rBM, and the
refined and reproducible conditions of traditional 2D cultures [58]. Many studies have
shown that tumor architecture and complexity can be reproduced using 3D cultures of
human-derived cells or organoids, which enable the investigations of specific
communications between neighboring cells and the effects of non-cellular factors (e.g.,
hypoxia and acidosis) within defined tumor microenvironments. Here, we are introducing a
3D in vitro breast cancer avatar and discussing the integration of these avatars into
environmentally controlled chambers to perform live-cell imaging and secretome (i.e., the
total organic and inorganic molecules secreted by cells) analysis that accompany cell:cell
interactions over extended periods of time.

Author Manuscript

We developed a tractable 3D/4D (3D + time) rBM overlay culture model designated
mammary architecture and microenvironment engineering (MAME) as a compromise
between 2D in vitro culture and in vivo models. Our MAME models are extended and
refined from those of Bissell and Brugge [59,60]. The MAME models are pathomimetic
avatars of breast cancers and are being used for functional imaging of proteolysis and
morphometric analyses in real time during progression (Fig. 2). Detailed protocols for
establishing MAME cultures have been described previously [61]. In MAME cultures [62],
normal breast epithelial cells and tumor cells show strikingly similar characteristics to the
same cells grown as orthotopic xenografts in vivo [63]. We have also observed degradation
of DQ-collagens in MAME models and identified cysteine cathepsins associated with tumor
progression by using ABPs (for example, see Fig. 1) [12,64]. Our MAME models also
enable the user to study cells grown in 3D in mixed or parallel co-cultures and analyze
dynamic and temporal changes in proteolytic activity in real-time, i.e., 4D.

Author Manuscript

We investigated whether the growth of breast epithelial cells in the MAME model could
replicate in vivo-like structures. Thus, we analyzed morphogenesis and oncogenic
transformation of human breast epithelial cells using MCF-10A cells. The MCF-10A cells,
non-tumorigenic breast epithelial cells, grown in MAME culture conditions proliferated and
formed unique 3D structures not seen in 2D culture conditions. Immunostaining for the
basal receptor, integrin α6, shows the formation of spheroids that develop into acini with
central lumens, resembling acinar structures of mammary lobules [62]. When the isogenic
MCF-10A progression series of cell lines, c-H-ras transformed MCF10AneoT [63,65] and
non-invasive MCF10AT1 [63], were analyzed under the same conditions, they formed
simple duct-like structures with no central lumens and multi-acinar structures, which are
typical of in vivo-like phenotypes of benign hyperplastic and atypical hyperplastic lesions,
respectively. In MAME models, during the transition of ductal carcinoma in situ (DCIS)
cells, MCF10.DCIS, to invasive ductal carcinomas cells, MCF10.CA1d, there was a change
a change in morphology from large dysplastic structures to invasive structures, along with
loss of the expression of integrin α6 [62]. Indeed, the morphologies of these cells in MAME
cultures accurately imitate their in vivo behavior. Additionally, experiments with GB111, an
Biochimie. Author manuscript; available in PMC 2017 March 01.
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ABP for the detection of cysteine cathepsins [62], revealed that cathepsin B promotes
proliferation and malignant progression of breast epithelial cells, which is consistent with
animal studies showing reduced tumorigenic capacity in cathepsin B-deficient mouse
models [66] and increased tumor growth in cathepsin B-overexpressing mouse models [67].

Author Manuscript

One important non-cellular factor that affects tumor progression in vivo is acidosis.
Adjusting acidic conditions to mimic levels found in the in vivo tumor microenvironment
(i.e., pH 6.8) in conjunction with the use of DQ-collagen IV showed an increase in
degradation of this substrate in the peritumoral regions of MDA-MB-231 breast carcinoma
cells as compared to those grown at a neutral pH of 7.4 (Fig. 1A–C) [12]. Moreover, using
GB123, an ABP for cysteine cathepsins, we demonstrated increases in the secretion of active
cathepsin B at pH 6.8, which contributed to increased degradation of collagen IV (Fig. 1).
These results are consistent with the fact that acidity generated within the tumor
microenvironment enhances tumor invasion in vivo by inducing secretion of active cathepsin
B [68].

Author Manuscript

We have also addressed specific cell crosstalk between breast carcinoma cells and
surrounding stromal cells including fibroblasts, adipocytes, and endothelial cells within an in
vivo-like human tumor microenvironment using MAME models. Among these cells,
fibroblasts are the most abundant cell types and their infiltration into tumors with extensive
loss of basement membrane is observed during malignant progression from pre-invasive
DCIS to invasive breast carcinoma. Co-culturing of MCF10.DCIS cells in MAME models
with mammary fibroblasts overexpressing stromal-derived hepatocyte growth factor (HGF)
(MF:HGF) or in the presence of conditioned media from the fibroblasts results in increased
invasiveness and development of invasive outgrowths by the MCF10.DCIS cells [69].
Enhanced degradation of extracellular DQ-collagen IV was also observed in MCF10.DCIS
cells co-cultured with MF:HGF. The mechanism by which HGF promotes the invasive
nature of these cells is through activation of c-Met and stimulation of secretion of urokinase
plasminogen activator (uPA) and its receptorm uPAR. Xenografts formed by co-injection of
MCF10.DCIS cells and MF:HGF exhibit significant increases in progression to invasive
ductal carcinomas, consistent with the results in vitro in MAME cultures [69]. In other
studies, we have shown that degradation of DQ-collagen IV by tumor cells co-cultured with
fibroblasts was further augmented by addition of macrophages [70], consistent with studies
by others showing the importance of stromal cells, and in particular inflammatory cells, for
the study of tumor proteolysis [47,66,71].

Author Manuscript

Other applications in which we are using MAME models are for the analysis of
immunotherapeutic approaches with armed activated T cells targeting breast carcinoma
cells, photodynamic therapy against inflammatory breast cancer cells, and therapy with
small molecule kinase inhibitors or cytokine blocking antibodies against breast carcinoma
cells (unpublished results). We contend that MAME models provide a tractable and
controllable environment into which one can incorporate specific cells, growth factors, and
probes for functional imaging including imaging in real-time of proteolysis by live cells. In
addition to delineating biological mechanisms during tumor development, MAME models
also serve as reliable platforms for generating predictive preclinical results before in vivo
evaluation of drugs.
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4. Applications of tissue architecture and microenvironment engineering
(TAME) chambers beyond live-cell imaging of proteolytic activity
We saw the need to develop an imaging modality, which not only maintains the well-defined
microenvironment present in our MAME models, but also allows the ability to grow cultures
undisturbed for extended periods of time. Our MAME models have some limitations as an
avatar for cancer research, including the: 1) inability to examine the effects of secreted
factors on cell:cell interactions over extended periods; and 2) difficulty in evaluating cell
migration in complex co-cultures. Therefore, the MAME models restrict study of the
dynamic nature of tumor proteolysis over extended periods of time. In addition, we also had
an interest in developing a model to monitor changes in secretome proteins, cell:cell
interactions, migration, morphology, and other factors implicated in tumor growth (e.g.,
hypoxia and acidosis) in real-time.
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In line with the MAME models that our lab has developed, we designed a new imaging
platform, the tissue architecture and microenvironment engineering (TAME) chamber. The
TAME chamber supports long-term growth of cell cultures and is designed for live-cell
imaging. We have developed platforms with single well chambers and dual-well chambers
connected by a small channel that can support monoculture, direct co-culture, or parallel coculture studies. To date, we have cultured human breast carcinoma cells in monoculture and
parallel co-cultures with human breast carcinoma-associated fibroblasts (CAFs) and normal
breast fibroblasts (NFs) on our platform for >60 days. These cultures were allowed to grow
undisturbed for the entire experiment only requiring media changes every seven days at
which time conditioned media was collected for secretome analysis. Cells were labeled with
vital dyes thus enabling live-cell imaging by confocal microscopy over the entire length of
the experiment. We were able to detect differences in fibroblast migration toward tumor cells
as well as changes in tumor cell morphology over time depending on whether they were in
monoculture or parallel co-culture with CAFs or NFs. CAFs, but not NFs, could be detected
infiltrating into tumor-like structures when grown in parallel co-culture with tumor cells, as
shown in the cartoons of Fig. 3. Planned studies with TAME chambers include the study of
dynamic changes in the secretome of breast cancer cells in monoculture as compared to
parallel co-culture with various fibroblast cell lines, as well as, determining whether CAFs
are capable of preferentially migrating toward other breast cancer cell lines in our TAME
chamber model. Since one focus of our lab is the study of proteolysis by live-cell imaging,
we are also interested in imaging proteolysis in these same cultures over 60 days. In an effort
to make our models better able to mimic the conditions of the tumor microenvironment, we
are in the process of developing novel pH and oxygen sensors that will allow us to monitor
the effects of acidic and hypoxic microenvironment conditions over extended periods of time
in TAME chambers.
We believe that the TAME chamber represents a powerful new tool for studying the complex
and dynamic nature of tumor kinetics and could potentially be developed as a drug screening
platform. Indeed, this model can support drug screening studies in which cultures are seeded
onto rBM and allowed to form 3D structures prior to adding therapeutic agents.
Furthermore, the analyses can be carried out in real-time and over extended periods of time.
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This can include quantification of dynamic responses of cell:cell and cell:matrix
interactions, growth, cytotoxicity, and cytokine/chemokine secretion. Since the TAME
chamber is designed to support imaging studies, its use as a drug screening platform allows
for the study of therapies that directly target tumor cells, tumor proteolysis, other cells
associated with tumors such as fibroblasts and inflammatory cells or non-cellular features of
the tumor microenvironment such as acidosis. It also could be useful as a model for studying
tumor re-growth after drug treatment and thus a key to better understanding cancer drugresistance and recurrence. One could potentially use the platform as a modality for
developing new immunotherapies: cancer vaccine formulation could be supported by the
arrangement of complex co-cultures between antigen-presenting cells and T-cells to test the
ability of a particular antigen to activate T-cell response.
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Some have proposed the development of personalized patient-derived xenograft models for
the purposes of testing drug therapies concurrently with patient treatment as a method of
predicting patient drug responses [72,73]. The limits of these models include the cost and
number of mice required for such analyses. It may also be legitimate to question the ability
of personalized mouse models to produce life-saving results and insights since xenograft
models are notorious for being biased toward false positive results [74]. Also important to
note is that tumors are intrinsically heterogeneous and genetically unstable, and so the
feasibility and reliability of such models may be of concern. Many recent studies and
reviews have been published using patient derived organoids to support genetic,
microenvironment and drug screening studies [75–77]. Many of these platforms require
organoid splitting every week therefore disturbing the organoid cultures. While this may
have minimal effects on studying certain aspects of organoid culture or drug efficacy, others
analyses such as proteolysis, secretion and cell:cell interactions require that the cultures not
be disturbed. Our TAME chambers should be useful for establishing patient derived
organoids for long term, undisturbed live-cell imaging studies on drug efficacy, phenotypic
changes, and tumor proteolysis.

5. Perspectives
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The association between protease activity and cancer progression was first reported in 1946
[78]. Protease-targeted imaging probes including SBPs and ABPs to monitor and visually
identify active proteases, or proteolytic activities, have been utilized and applied in the study
of many pathologies including cancer. Several challenges for these probes remain to be
addressed: 1) SBPs can be used to measure accumulated proteloytic activities with signal
amplification over time, but do not allow direct identification of a target protease(s), and 2)
ABPs bind covalently to a single target protease, but may modify proteases and do not
amplify signals. Thus, comparative studies using these two types of probes could provide
valuable information with each compensating for the limitations of the other. In addition,
improved cell permeability, selectivity, stability, and imaging resolution need to be
considered for the development of future imaging probes.
The limits of traditional 2D cell culture models and even in vivo models for cancer research
have become evident over the last few decades. Thus, the development of 3D pathomimetic
avatars for studying various aspects of tumor biology, including proteolytic activity, has
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enabled the robust recapitulation in vitro of a wide array of factors of the in vivo tumor
microenvironment. Hence, avatars such as the MAME and TAME models developed by our
group, represent a powerful modality enabling study of complex co-cultures, long-term
analysis of proteolysis and secreted factors (e.g., cytokines), and have the potential to be
useful as a drug screening platform. Our convergence of MAME culture models and TAME
chambers has many advantages: 1) dynamic analysis of spatio-temporal cell:cell
interactions, 2) co-culturing of multiple cell types, 3) introduction of engineered cells,
scaffold matrices, and conditioned medium, 4) real-time imaging of proteolysis using SBP
and/or ABPs in live cells, 5) quantification of real-time changes in cell volume and
proteolysis, 6) replenishment and/or collection of media without disturbing cultures, and 7)
manipulation of the extracellular pH and/or oxygen of the cultures in a controlled manner.
Moreover, while our current use of this model has been primarily in studying breast cancer,
this integrated system can be extended to other cell culture models representing both normal
and pathological conditions.
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We have used MAME avatars to determine the roles of cellular and non-cellular (i.e., pH)
components of the tumor microenvironment in progression of premalignant DCIS cells to an
invasive phenotype and reversion therefrom [(12, 69); M. Sameni and B.F. Sloane,
unpublished results]. In addition, we have used MAME avatars to demonstrate the ability of
neutralizing antibodies to interleukin 6 to reduce the invasive phenotype of tumor cells [79];
this is a class of antibodies that have been FDA-approved for treatment of Castleman's
disease. We have also used MAME avatars to determine the efficacy of drugs targeting MET,
vascular endothelial growth factor receptor (VEGFR) 2 and mitogen-activated protein kinase
(MEK) [(69); M. Sameni and B.F. Sloane, unpublished results], photocaged inhibitors of
cathepsin B (S. Ramalho and B.F. Sloane, unpublished results), and photodynamic therapy
sequentially targeting lysosomes and mitochondria (N, Aggarwal and B.F. Sloane,
unpublished results). These studies serve as proof-of-principle that MAME avatars will be
useful for screening of drugs and other therapeutic approaches. Moving the MAME avatars
into TAME chambers will increase the throughput and reproducibility of our analyses.
Moreover, it will allow us to manipulate the non-cellular aspects of microenvironment (e.g.,
pH and oxygen) in real-time, alter conditions of drug delivery at selected time points and
collect media for analysis of the secretome without disturbing the cultures. Ongoing efforts
to adapt the TAME chambers for high content analysis should further increase the value of
the converged MAME:TAME system as a valuable and versatile screening platform.
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CAFs

carcinoma-associated fibroblasts

DCIS

ductal carcinoma in situ

DQ

dye quenched

ECM

extracellular matrix

FRET

fluorescence resonance energy transfer

HGF

hepatocyte growth factor

MAME

mammary architecture and microenvironment engineering

MMP

matrix metalloproteinase

NFs

normal human breast fibroblasts

rBM

reconstituted basement membrane

SBPs

substrate-based probes

TAME

tissue architecture and microenvironment engineering

uPA

urokinase plasminogen activator
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Fig. 1.

Live cell imaging of proteolysis in 3D MAME cultures. MDA-MB-231 cell were grown in
3D rBM overlay cultures, at pH 6.8, in the presence of either DQ-collagen IV (A–C) or
GB123 activity-based probe for cysteine cathepsins (D–F). Insets illustrate cultures grown at
pH 7.4. Top panels depict images of entire 3D volume of cells (red), nuclei (blue) and DQcollagen IV degradation products (green) (A); entire 3D volume of DQ-collagen IV
degradation products only (B), and intensity maps for DQ-collagen IV degradation products
(white, most intense; violet, least intense) (C). Bottom panels depict images of the entire
volume of cells (red) and total (pericellular plus intracellular) active cysteine cathepsins
bound to GB123 (cyan) (D); pericellular bound GB123 only (E) and intracellular bound
GB123 only (F). Bars, 22.6 μm. Adapted from Rothberg et al., 2013. Neoplasia [12].
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Fig. 2.
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Schematic illustrations of normal versus cancerous human breast cells within the in vivo
breast microenvironment (A) and as modeled in our 3D MAME avatars (B). In vivo, normal
human breast ducts, comprised of myoepithelial cells and luminal epithelial cells (i.e.,
epithelial cells lining the lumen) (A, gray dashed box), grow in a controlled normoxic and
neutral pH microenvironment. In contrast, breast cancer cells interact with adjacent and
infiltrating stromal cells (e.g., fibroblasts, inflammatory cells, endothelial cells, and
adipocytes) (A, orange dashed box) and grow irregularly in a hypoxic and acidic tumor
microenvironment. Our 3D MAME avatars are designed to mimic in vivo normal and
cancerous breast tissues (B). Normal epithelial cells grown in 3D MAME cultures form
acinar structures with lumens resembling normal breast tissue (B, top image) and exhibit a
basal level of DQ-collagen IV degradation (green). In comparison, breast ductal carcinoma
in situ cells grown in 3D MAME cultures form larger, irregular and dysplastic structures (B,
middle image). Co-cultures of breast carcinoma cells and fibroblasts result in an invasive
morphology and increased degradation of DQ-collagen IV (B, bottom image). A was
modified from Nelson and Bissell, 2005. Seminars in Cancer Biology [80].
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Fig. 3.
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Cartoons illustrating distribution of breast cancer cells and normal fibroblasts (NFs; upper)
or carcinoma-associated fibroblasts (CAFs; lower) grown in parallel cocultures in TAME
chambers. Breast cancer cells (pink circles) and fibroblasts (green) were imaged live to
follow cell:cell interactions and movement over a 63 day period. Green arrows indicate the
observed migration of fibroblasts over this period. CAFs, but not NFs, migrated
preferentially toward breast cancer 3D structures.
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